FDG-PET in Predicting Response Rates in Triple-Negative Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

The assessment of metabolic response and epidermal growth factor receptor (EGFR) using fluorodeoxyglucose positron emission tomography (FDG-PET) may assist physicians in predicting the likelihood of achieving pathological complete response (pCR), according to an article published online in the journal Clinical Cancer Research.

The authors of this study aimed to assess the response of metabolic tumors to 18F- FDG-PET compared to using clinicobiological markers to predict pCR to neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC).

Participants included 50 women diagnosed with TNBC and an indication for NAC. Evaluated factors included pre-treatment clinical, biological, and pathological biomarkers (eg, Scarff-Bloom-Richardson [SBR] grade, the Ki-67proliferation index, EGFR).

Furthermore, FDG-PET was used to assess the baseline tumor glucose metabolism and its change after the first cycle of NAC (ΔSUVmax).

Results showed the pCR rate (42%) was associated with a high Ki-67 proliferation index (P=0.016), a negative EGFR result (P=0.042), and a high ΔSUVmax (P=0.002). Negative EGFR status (OR=6.4; P=0.043) and high ΔSUVmax (OR=7.1; P=0.014) were both determined to be independent predictors of pCR.

A combination of a low ΔSUVmax and a positive EGFR status result predicted non-pCR in patients with a 92% accuracy.

PIK3CA, PAM50 Do Not Predict Adjuvant Trastuzumab Response in HER2-Positive Breast Cancer
Assessment of metabolic response and EGFR using FDG-PET may assist physicians in predicting the likelihood of response.
Researchers investigated the value of the metabolic tumor response assessed with FDG-PET, compared with clinico-biological markers to predict pCR to neoadjuvant chemotherapy in women with triple-negative breast cancer.
READ FULL ARTICLE From clincancerres.aacrjournals.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs